Cancer

Our Nu.Q^® Cancer pillar encapsulates a range of simple, cost-effective blood-based assays for cancer, utilizing our patented Nucleosomics™ technology which isolates circulating nucleosomes from the blood for quantification and analysis.

Nu.Q^® Cancer can detect characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer and has potential applications beyond cancer detection. Being able to use epigenetic information from the nucleosomes of tumor cells could help physicians predict treatment response for each patient, monitor treatment response and disease progression, and take action as soon as possible if changes need to be made.

Nu.Q^® Cancer could also play a pivotal role in Minimal Residual Disease Monitoring – to quantify and monitor the small number of cancer cells left in the body after cancer treatment, which have the potential to cause relapse.

In addition, we have developed a novel method for liquid biopsy involving the first reported physical isolation of a class of tumor-derived ctDNA fragments from blood. Our breakthrough method obviates expensive, time-consuming DNA sequencing and bioinformatics – allowing for rapid, cost-effective detection in a routine blood test.